Development and evaluation of a multiplex microsphere assay for quantification of IgG and IgA antibodies against Neisseria meningitidis serogroup A, C, W and Y polysaccharides by Bårnes, Guro Kristine et al.
Development and Evaluation of a Multiplex Microsphere Assay for
Quantitation of IgG and IgA Antibodies against Neisseria meningitidis
Serogroup A, C, W, and Y Polysaccharides
Guro K. Bårnes,a,b Paul A. Kristiansen,a Dominique A. Caugant,a,b Lisbeth M. Næssa
Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norwaya; Department of International Health, University of Oslo, Oslo, Norwayb
We developed and evaluated a rapid and simple multiplex microsphere assay for the quantification of specific IgG and IgA anti-
bodies against meningococcal serogroup A, C,W, and Y capsular polysaccharides in serum and saliva. Meningococcal polysac-
charides were conjugated to distinct magnetic carboxylated microspheres, and the performance of the assay was assessed using
the CDC1992 standard meningococcal reference serum and a panel of serum and saliva samples. The standard curve was linear
over an eight 3-fold dilution range in the IgG assay and a seven 3-fold dilution range in the IgA assay. No cross-reactivity was
discovered, and the assay showed high specificity with>91% homologous inhibition and<11% heterologous inhibition for all
serogroups and immunoglobulin classes. Lower limits of detections were<280 pg/ml for IgG and<920 pg/ml for IgA antibod-
ies. The assay was reproducible, with a mean coefficient of variation of<5% for intra-assay duplicates, a mean coefficient of vari-
ation of<20% for interassay repeated analysis with different conjugations of microspheres, and a mean coefficient of variation
within 25.8% for interoperator variation. The assay showed good correlation to the standard meningococcal polysaccharide en-
zyme-linked immunosorbent assay (ELISA) for detection of serum antibodies. This multiplex assay is robust and reliable and
requires less sample volume, and less time and workload are needed than for ELISA, making this method highly relevant for se-
rological and salivary investigations on the effect of meningococcal vaccines and for immunosurveillance studies.
Meningococcal disease continues to be a significant publichealth problem, although vaccines used in national immu-
nization programs or mass vaccination campaigns have reduced
the incidence of the disease in several countries (1). The capsular
polysaccharide is an important antigen and virulence factor (2),
and the most widely used meningococcal vaccines are based on
these polysaccharides. Such vaccines have been shown to be effec-
tive for serogroups A, C, W, and Y, four of the five major disease-
causingmeningococcal serogroups (1, 3), and have been available
and widely used for nearly half a century.
To evaluate the effect of meningococcal vaccines and deter-
mine protection against disease, serogroup-specific serological
measures are used. Serum bactericidal activity (SBA) has become
the most widely used surrogate of protection and is the basis for
licensure of the recent meningococcal vaccines (4). However, this
method is highly time consuming and requires specialized labo-
ratories and highly standardized biological reagents. Quantitation
of specific anti-meningococcal polysaccharide antibodies, on the
other hand, is more suitable for large immunosurveillance studies
and contributes to a broader understanding of the immune re-
sponse. In a vaccine efficacy trial in Finland in the 1970s, a specific
immunoglobulin G (IgG) concentration was shown to correlate
with clinical protection against serogroup A disease (5). The most
common method for antibody quantitation has been enzyme-
linked immunosorbent assay (ELISA). ELISA can only measure
antibodies against one antigen at a time and is, therefore, labor
intensive. In an era where the use of multivalent vaccines is in-
creasing, assays that give the opportunity for multiplexing, that is,
testing simultaneously for several analytes within the same sam-
ple, provide huge advantages and enhance effectiveness several-
fold. Several multiplexing techniques have been developed, but
since the first particle-based flow cytometric assays became avail-
able in the early 1980s, such methods have become increasingly
popular. Multiplex assays substantially reduce the cost, time, and
sample volumes required, have a wider analytical range than that
of the ELISA, and several studies have shown them to be sensitive,
specific, reproducible, and accurate (6–9). Thus, assays based on
this technique have been developed for detection of a wide range
of antibodies, antigens, genetic material, and etc. (10).
In particle-based assays, antigens are conjugated onto micro-
scopic spheres (beads). Using polysaccharides as antigens in such
assays, however, poses a challenge, as they are not able to cova-
lently bind directly with polystyrene microspheres as proteins do.
Polysaccharides need a couplingmolecule and, thus, an additional
step for conjugating them onto the microspheres. Several meth-
ods for conjugation to microspheres have been developed using
polysaccharides from different bacterial species (6, 8, 9, 11–15). A
comparative study of different coupling agents showed that the non-
toxic 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium
(DMTMM)was the overall preferred coupling agentwhen conjugat-
ing pneumococcal polysaccharides to microspheres (15). We as-
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sumed that these findings could be transferred to the development of
a meningococcal polysaccharide assay.
Multiplex methods for detection of salivary antibodies have
been developed and evaluated for other pathogens (16). A multi-
plex assay developed for measuring IgG antibodies in serum was
used for quantification of anti-meningococcal serogroup C anti-
bodies in saliva (17, 18). However, to enable investigation of the
salivary immune response tomultivalentmeningococcal vaccines,
a multiplex assay for use on saliva as well as serum samples, was
developed and evaluated. Additionally, this allowed the possible
investigation of the relationship between antibody responses in
serum and saliva and the potential for using saliva as a substitute
for serum to measure systemic antibody responses (19). The
method described here detected anti-polysaccharide IgG and IgA
antibodies against the four meningococcal serogroups A, C, W,
and Y.
MATERIALS AND METHODS
Test and reference samples. Standard human reference serumCDC1992
(National Institute of Biological Standards and Control [NIBSC] code
99/706, pooled sera from 14 adults vaccinated with ameningococcal A, C,
W, and Y polysaccharide vaccine) was obtained from NIBSC, and the
serogroup-specific concentrations of IgG and IgA antibodies previously
assigned to it were used for quantification of samples (20, 21). To develop
and evaluate the assay, a control panel of 15 serum and 15 saliva samples
were established. The samples in the panel were chosen to cover a wide
range of different concentrations of specific anti-meningococcal IgG and
IgA antibodies to cover the dynamic range of the assay. These samples
were obtained from employees at the Norwegian Institute of Public
Health (NIPH) before and after routine preventive meningococcal vacci-
nation with a tetravalent conjugate vaccine (Menveo; Novartis Vaccines)
due to occupational risk. Additional samples used for the correlation as-
says were obtained fromhealthyNorwegian individuals, either vaccinated
with Menveo meningococcal vaccine or unvaccinated, whose samples
were submitted to the NIPH for anti-meningococcal antibody screening,
and randomly selected saliva samples from a study in 10- to 14-year-old
patients before and after vaccination with a serogroup A conjugated vac-
cine (MenAfriVac) in Burkina Faso (22). The study obtained all necessary
ethical approvals. All samples used for development of the assay were
deidentified.
Conjugation of Neisseria meningitidis capsular polysaccharide to
microspheres. Meningococcal polysaccharides were conjugated to mag-
netic microspheres (MagPlex COOH microspheres, size 6.5  0.2 m;
Luminex Corp., TX, USA) based on the method developed for pneumo-
coccal polysaccharides by Schlottmann et al. (15).N.meningitidis purified
capsular polysaccharides were obtained from NIBSC (United Kingdom),
serogroup A (NIBSC code 98/730), serogroup C (07/318), serogroup W
(01/428), and serogroup Y (01/426), and reconstituted in sterile water to a
concentration of 1 mg/ml. A volume of 875l of each polysaccharide was
treated with 70 l of a 200 mg/ml solution of 4-(4,6-dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (Sigma-Al-
drich, MO, USA) in sterile water. The polysaccharide/DMTMM mixture
was incubated in the dark, on a rotator, for 1 h at room temperature (RT).
After incubation, the mixture was added to a Sephadex G-25M PD10
column (GE Healthcare, United Kingdom) equilibrated with phosphate-
buffered saline (PBS) (in-house; containing 5.53mMdisodium hydrogen
phosphate, 1.13 mM sodium dihydrogen phosphate, and 138.6 mM so-
dium chloride; pH 7.4) and eluted with 3.5 ml of PBS to separate the
DMTMM-modified polysaccharides from free DMTMM, giving a calcu-
lated final polysaccharide concentration of 0.25mg/ml. Different polysac-
charide concentrations were tested individually for each serogroup, and,
showing only small differences in all serogroups, a final concentration of
0.25 mg/ml for each polysaccharide was found to give the overall best
standard curves, with regard to range and fluorescent intensity. Five hun-
dredmicroliters ofmodified polysaccharidewas added to 500lmagnetic
microspheres (1.25  107 microspheres/ml), vortexed, sonicated, and
incubated in the dark on a rotator at RT overnight. The following day,
using a magnetic holder, the conjugated microspheres were rinsed twice
with 0.5ml of PBS-Tween 0.05% (PBST) to remove noncovalently bound
modified polysaccharides before adding 500 l of blocking buffer (PBS
with 10% bovine serum albumin [Gibco; Thermo Fisher Scientific, Inc.,
MA, USA], 0.05% sodium azide). Conjugated microspheres were stored
at 4°C in the dark.
Multiplex microsphere assay for quantification of anti-meningo-
coccal polysaccharide IgGand IgAantibodies.Conjugatedmicrospheres
were vortexed, sonicated, and diluted to a final concentration of 2,500
microspheres perwell of each serogroup in 50l dilution buffer (PBSwith
10% antibody-depleted human serum [Valley Biomedical, VA, USA]),
which was the volume added to each well of a 96-well Nunc flat-bottomed
plate (Bio-Rad, United Kingdom). Different concentrations of anti-
body-depleted human serum in the dilution buffer were tested to find
this optimal concentration. Standard meningococcal reference serum
CDC1992 was 3-fold diluted (1:50 to 1:109,350). From the control panel,
two in-house control serum samples, one at the upper end and the other at
the lower end of the standard curve, were selected and diluted 1:1,000 or
1:100, respectively. These controls were included in each run to evaluate
the run. Serum samples were diluted in the range from 1:100 to 1:1,600,
and 50 l of each prediluted serum sample was added to the wells. Saliva
samples were diluted from 1:1 to 1:20 directly in wells. Samples and mi-
crospheres were incubated for 1 h. All incubation steps were done on a
plate shaker set to 600 rpm at RT and in the dark. The plates were washed
three timeswith PBSTusing amagnetic washer. For the IgG assay, 50l of
R-phycoerythrin (PE)-conjugated anti-human IgG (Sigma-Aldrich, MO,
USA) diluted to 1:200 in PBSwas added and incubated for 25min. For the
IgA assay, 50 l of a 1:1,000 dilution of monoclonal mouse anti-human
IgA (Sigma-Aldrich, MO, USA) was added and incubated for 25 min
before adding 50 l of a 1:200 dilution of R-PE-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch, Inc., PA, USA) and subsequently
incubated for another 25 min. Various concentrations of all secondary
antibodies were tested. After incubation with secondary antibodies, plates
were washed and microspheres resuspended in 125 l of PBS. Results
were read on a Bio-Plex reader (Bio-Rad, United Kingdom) detecting
fluorescent intensity, and Bio-Plex Manager 6.1 software (Bio-Rad,
United Kingdom) was used to generate a 5-parameter log-log standard
curve for analyzing mean fluorescent intensity (MFI) of unknown sam-
ples against the known concentrations of reference serum CDC1992 to
determine Ig concentrations in the samples.
Assay sensitivity. The sensitivity of the multiplex assay was deter-
mined by comparing the values from blank wells to the standard curve, as
described previously (8), with slight modifications using 24 blank wells in
three different runs with different batches of conjugatedmicrospheres for
the calculations. The lower limit of detection (LLOD) in picograms per
milliliter was calculated from the relevant standard curve, based on the
averaged MFIs, with two positive standard deviations. This was done for
each serogroup and for IgG and IgA.
Assay specificity.To assess assay specificity, we tested reference serum
CDC1992 in an inhibition assay, adding free polysaccharides. Homolo-
gous free polysaccharideswere expected to cause close to 100% inhibition,
whereas heterologous free polysaccharides were not expected to cause any
inhibition. Reference serum was diluted 1:100 in dilution buffer and in-
cubated for 1 h with 2.5g/ml of each polysaccharide, as described by Lal
et al. (8). Reference serum with no added polysaccharides was used as a
control and all dilutions were run as regular samples in either the IgG or
IgA multiplex assay.
Assay precision. For determination of intra-assay precision, dupli-
cates of different serum (n 15) and saliva (n 15) samples were used.
Coefficient of variation (CV) was calculated for each duplicate and then
averaged.
For interplate precision, 15 serum and 15 saliva samples were analyzed
Bårnes et al.
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in three different runs on different days and with three different lot prep-
arations of conjugated microspheres and other reagents. The percent CV
across these three assays was calculated for each sample and averaged.
Interoperator precision was determined from assays run by three dif-
ferent operators, of whom two had limited experience with this assay. The
assays were performed on different days, using different lots of conjugated
microspheres. The percent CVs of serum (n  14) and saliva (n  16)
samples were calculated and averaged.
Stability. The stability was assessed by comparing MFIs of standard
curves generated in assays performed within 1 week after polysaccharide
conjugation to microspheres to standard curves generated in assays per-
formed with microspheres that had been stored for 3 and 6 months after
conjugation, aswell as comparing percentages of aggregatedmicrospheres
(26). In addition, Ig concentrations in serum and saliva samples were
analyzed at these same time points and compared. Stability of the
DMTMM-modified polysaccharides was assessed by comparison of mi-
crospheres conjugated with polysaccharides freshly modified with
DMTMM and after storing the modified polysaccharides for 4 months at
20°C. Furthermore, the stabilities of the test samples were assessed by
reading plates at different times (1 h, 3 h, 1 day, and 2 days) after the assay
was finished, storing the plates at 4°C, and shaking them for 5min prior to
reading.
ELISA for quantification of anti-meningococcal polysaccharide IgG
and IgA antibodies. The IgG and IgA ELISA procedure was performed as
previously described (23) with some modification. In brief, Nunc Maxi-
Sorp 96-well microtiter plates (Thermo Fisher Scientific, Inc., MA, USA)
were coated with serogroup A, C,W, or Ymeningococcal polysaccharides
in complex with methylated human serum albumin at a final concentra-
tion of 10 g/ml of each component. Coated plates were incubated over-
night and stored up to 14 days at 4°C. The day of analysis, plates were
washed in PBS with 0.1% Brij and 0.02% sodium azide and incubated for
1 h at RTwith 3% fetal calf serum (FCS) in PBS with 0.02% sodium azide.
Samples were set up in two dilutions, serum samples diluted from1:100 to
1:1,000 and saliva samples diluted at 1:5 to 1:20, in dilution buffer con-
taining PBS with 3% FCS, 0.1% Brij, and 0.02% sodium azide. Serial
2-fold dilutions of reference serum CDC1992 were prepared in the range
from 1:100 to 1:12,800. Test sample or reference serum was added in
duplicate, 100 l to each well. The microtiter plates were then incubated
overnight at 4°C. After washing, secondary alkaline phosphatase antibod-
ies, goat anti-human IgG (gamma chain specific), or goat anti-human IgA
(alpha chain specific) from Sigma-Aldrich (MI, USA), were added and
plates were further incubated at 37°C for 2 h. After beingwashed, 100l of
1 mg/ml p-nitrophenyl phosphatase substrate (Sigma-Aldrich, MI, USA)
prepared in an in-house 10% diethanolamine buffer was added to each
well. Optical density (OD) values were read at 405 nm on an Emax plate
reader (Molecular Devices, United Kingdom) when the reference serum
at dilution 1:100 had reached an OD of approximately 2. IgG or IgA
antibody concentrations were calculated against the standard reference
curve using a 4-parameter logistic curve-fitting analysis in SoftMax 2.35
computer software.
Statistical analysis. Statistical analyses were done using Stata SE/13,
GraphPad Prism 5, and Microsoft Excel 2010 software.
RESULTS
Development of a multiplex microsphere assay for quantifica-
tion ofmeningococcal serogroup-specific IgG and IgA antibod-
ies. Each polysaccharide was conjugated onto distinct micro-
spheres and initially run in monoplex to evaluate the range of
fluorescent intensity and the linearity of the standard curve. The
standard reference serum showed good linearity over an eight
3-fold dilution range in the IgG assay and a seven 3-fold dilution
range in the IgA assay.Weused a 3-fold dilution ranging from1:50
to 1:109,350, as dilutions of1:50 appeared to be above the point
of saturation for serogroup A and C in the IgG assay and dilutions
of 1:109,350 reached the values of the blank for serogroup W
and Y in the IgA assay.When analyzing serum samples at different
dilutions from 1:100 to 1:1,600, parallelism with the standard
curve was observed for all dilutions (24). When analyzing saliva
samples, on the other hand, a dilution of 1:1 appeared to be too
concentrated, giving lower values (prozone), whereas a 1:20 con-
centration seemed to overestimate antibody levels, and linearity
was shown only in the dilution range from 1:5 to 1:10.
To ensure that only those antibodies directed against the poly-
saccharide originally conjugated to the distinctmicrospheres were
detected and to rule out migration of conjugate between micro-
spheres or interference when the microspheres were mixed into a
multiplex, averagedMFIs generated from three runs in themono-
plex assay were compared to averaged MFIs generated from three
runs in the multiplex assay. For all serogroups, there was virtually
no difference inMFIs of the standard reference serumbetween the
monoplex and multiplex for IgG (Fig. 1) and IgA (Fig. 2).
Different concentrations of microspheres added to each well
were tested with no difference in results, although an increase in
reading timewas observedwhen using1,500microspheres/well.
A concentration of 2,500 microspheres/well was chosen, as it was
considered practical to avoid using excessive amounts of expen-
sive microspheres but still resulted in reasonable reading times
(approximately 45 min for a full 96-well plate) and gave the op-
portunity to reanalyze the assay if some unexpected error oc-
curred.
Assay sensitivity. Sensitivity of the IgG and IgA assays was
determined by calculations from blank wells. The LLOD was cal-
culated from the corresponding standard curves and was 280
pg/ml for IgG and920 pg/ml for IgA (Table 1). Although low in
each assay, there was a significant difference in sensitivity for IgG
and IgA antibodies in all serogroups.
Assay specificity. To ensure that the assay measured sero-
group-specific antibodies only and that the polysaccharides had
not been altered in the conjugation process, an inhibition speci-
ficity assay was performed. The MFIs of the standard reference
serum generated in the different assays are shown in Fig. 3. Very
good specificitywas observed for all serogroups, with homologous
inhibition for all serogroups of92% in the IgG assay and91%
in the IgA assay and heterologous inhibition of11% in the IgG
assay and 6% in the IgA assay. The same inhibition assay was
performed with in-house serum controls showing the same good
specificity, but when analyzing in-house saliva controls, some
cross-reactivity between serogroup W and Y was observed (data
not shown).
Assay precision. The intra-assay CV was 5.1% for the IgG
and IgA assays against all four serogroups (Table 2).
The interassay precision was assessed with different conjuga-
tions ofmicrospheres and preparations of reagents to ensuremax-
imal variability and was overall very satisfactory, with mean per-
cent CV values for all serogroups, sample materials, and Ig classes
20% (Table 2). This suggested low assay to assay and batch to
batch variation of the conjugated microspheres. The interopera-
tor precision with different lots of microspheres was somewhat
higher, but all precision measurements were within 25.8% CV.
Stability. When assessing stability, by comparing MFIs of the
standard reference serum in assays using newly conjugatedmicro-
spheres and assays usingmicrospheres conjugated 3months and 6
months prior, there was a reduction in the MFI of 45% after 3
months and75% after 6 months (only analyzed for IgG). How-
ever, when quantifying serum and saliva samples using the refer-
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ence serum, there was no difference in Ig levels above normal
interassay variation. Additionally, therewas no actual loss in range
and no increase in bead aggregation during performance of the
assay (data not shown).
The ability to freeze and store theDMTMM-modified polysac-
charides was investigated after storage for 4 months at 20°C.
This revealed no difference above normal interassay variation
when comparing standard curves generated from microspheres
conjugatedwith fresh or storedmodified polysaccharide (data not
shown).
Reading of plates at different time points after completing the
assay showed no decline in MFI values and no difference in either
IgG or IgA concentrations in serum and saliva, although an in-
crease in the percentage of aggregated microspheres was observed
after 1 and 2 days: 4.3% in the original assay compared to 13.3%
and 8.3%, respectively, when averaged across the IgG and IgA
assay. When reading the same plates4 times, the required time
to detect sufficient amount of microspheres and read the MFI
increased but no difference in outcome was measured.
Comparison of themultiplexmicrosphere assaywith ELISA.
For comparison of the multiplex microsphere assay to the stan-
dardized meningococcal polysaccharide ELISA, a panel of 54 se-
rum samples and 16 saliva samples was analyzed with the two
methods, and concentrations of serogroup-specific IgG and IgA
antibodies were determined. The results were analyzed by linear
regression and correlation coefficients were calculated.Highly sig-
nificant correlations were found for IgG (Fig. 4) and IgA (Fig. 5)
antibodies in serum. When analyzing saliva samples, we did not
detect any consistent correlation between the two methods, with
correlation coefficients ranging from 0.02 to 0.8 (data not shown).
For further evaluation of the assay’s performance and suitabil-
ity to analyze salivary samples, a selection of saliva samples from
individuals before and after vaccination with a monovalent me-
ningococcal serogroup A conjugate vaccine, MenAfriVac, was an-
alyzed. These results showed an increase in specific anti-meningo-
coccal serogroup A IgG (P  0.023) and IgA (P  0.002)
antibodies after vaccination but no increase in anti-serogroup C,
W, and Y antibodies (Fig. 6).
DISCUSSION
We developed a meningococcal polysaccharide multiplex assay to
measure specific IgG and IgA antibodies and compared the results
with those obtained in conventional ELISA. The assay showed a
wide dynamic range, and the standard reference serum CDC1992
generated a linear standard curve over a21-fold dilution range.
When analyzing serum samples, parallelism with the standard
FIG 1 Mean fluorescent intensity (MFI) values generated with standard reference serum CDC1992 (NIBSC 99/706) when run as IgG monoplex and multiplex
assays.
Bårnes et al.
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curve was observed for a wide range of dilutions. However, when
analyzing saliva samples, this was true only in the dilution range
from 1:5 to 1:10. Thus, each sample was applied in one dilution
only for antibody determinations but with a much wider dilution
range for serum samples than that of saliva samples. TheMFI and
concentration levels in the 1:1 dilution of saliva, lower than those
of themore diluted samples,may be explained by interference due
to the viscosity or matrix effect of the saliva at a low dilution.
Despite this, a 1:1 dilution did not result in more variability, and
the results were consistent over several runs.
Cross-reactivity and interference were not observed when
comparing IgG monoplex and multiplex assays, suggesting that
only serogroup-specific antibodies were detected and that the
coupling of the modified antibodies to the microspheres was sta-
ble with no crossover of conjugate.
The inhibition assay showed high homologous inhibition
and low heterologous inhibition, suggesting that the polysac-
charides were not structurally altered by the DMTMM modi-
fication and conjugation process and remained intact after
coupling to the microspheres. The specificity was even better
than what has been found by others using poly-L-lysine (PLL)
as a coupling agent (8), which is consistent with findings by
Schlottmann et al. (15) when comparing the conjugation
methods for pneumococcal polysaccharides. When analyzing
saliva controls (n  2) in the same inhibition assay, on the
other hand, there appeared to be some cross-reactivity between
serogroup W and Y polysaccharides. As this was not seen in
serum, we believe it is not a reflection of poorer specificity of
the assay when analyzing saliva but a result of physiological
cross-reactivity of salivary antibodies induced by the very sim-
ilar structures of the W and Y polysaccharides (25).
The precision of the assay was good, with very low intra-assay
variation and limited lot to lot variation of coupledmicrospheres.
The interassay precision was all below 20% CV, whereas the
interoperator precision was, as expected, somewhat higher. How-
FIG 2 Mean fluorescent intensity (MFI) values generated with standard reference serum CDC1992 (NIBSC 99/706) when run as IgA monoplex and multiplex
assays.
TABLE 1 LLOD for IgG and IgA antibodies against serogroup A, C, W,
and Y meningococcal polysaccharides
Serogroup
LLOD (pg/ml) for:
IgG IgA
A 280 410
C 70 220
W 50 577
Y 100 920
Multiplex Assay for Anti-Meningococcal Antibodies
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ever, even when performed by operators with limited experience
with this assay, which is likely to increase the variation, the inter-
operator precision was acceptable.
Among the major advantages of multiplex assays is the reduc-
tion in time and labor due to analyzing four serogroups simulta-
neously, which is not possible in ELISA. For example, the time
spent analyzing 15 samples for all four serogroups was reduced
from 1.5 days in the ELISA to about 4 h in the multiplex assay.
Despite the fact that some of the reagents used in the multiplex,
especially the microspheres, are expensive, the reduction in time
and labor results in an overall reduction in costs. Performance of
the entire multiplex assay within 1 day, as well as no difference
seen if the plate is read repeatedly even after 2 days, permits flex-
ibility in the planning and execution of the laboratory work.
Maybe the most important advantage of the multiplex assay is
the reduction in required sample volume compared to that of the
ELISA. Minimizing the need for repeated analyses for each sero-
group and thereby conserving sample material is the most impor-
tant factor, but additionally, less sample volume in each assay is
required. This is highly relevant especially for saliva samples,
FIG 3 Mean fluorescent intensity (MFI) values generated with standard reference serum CDC1992 (NIBSC 99/706) for IgG and IgA following individual
incubation with either A, C, W, or Y free inhibitory polysaccharides. Incubation with dilution buffer only was used as a control.
TABLE 2 Precision of the multiplex assay
Parameter Sample type Serogroup A Serogroup C Serogroup W Serogroup Y
Intra-assay (mean % CV of duplicates)a
IgG Serum 3.3 3.4 3.9 4.5
Saliva 1.4 2.4 2.3 2.0
IgA Serum 3.4 5.1 5.0 4.5
Saliva 1.6 1.4 3.9 1.9
Interassay (mean % CV of samples)b
IgG Serum 12.6 16.2 19.7 16.7
Saliva 18.9 15.7 16.6 17.7
IgA Serum 13.2 10.7 12.4 16.2
Saliva 12.0 11.8 9.1 10.2
Interoperator (mean % CV of samples)c
IgG Serum 19.7 20.8 23.1 21.2
Saliva 15.1 23.9 25.8 25.6
IgA Serum 16.0 12.6 19.1 16.4
Saliva 14.6 19.9 22.6 17.0
a n 15.
b n 15; 3 different runs.
c n 14 (serum) and 16 (saliva); 3 different operators.
Bårnes et al.
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which may be difficult to obtain in large enough quantities to
analyze in multiple assays, as they cannot be diluted to the same
extent as serum samples. In order to analyze salivary IgG and IgA
antibodies against all four serogroups, one only needs 1/30 to 1/60
of the volume necessary for the same analysis in ELISA.
Two other important features of the multiplex assay also favor
the use of such an assay when analyzing samples with low levels of
antibodies, i.e., saliva: greatly increased sensitivity and dynamic
range. The LLOD is280 pg/ml for IgG and920 pg/ml for IgA
and shows the good sensitivity of the assay. The assay was reliable,
with acceptable interassay CVs for samples with antibody levels as
low as 1.5 ng/ml. However, samples with values 1 ng/ml had
FIG 4 Correlation of serogroup-specific anti-meningococcal polysaccharide IgG antibody concentrations in serum samples (n 54) measured by ELISA and
multiplex assays.
FIG 5 Correlation of serogroup-specific anti-meningococcal polysaccharide IgA antibody concentrations in serum samples (n 50) measured by ELISA and
multiplex assays.
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high increased interassay CVs (70%), which may suggest that
the lower limit of quantitation for the assay may be around 1,000
pg/ml. Nonetheless, an LLOD of 1 ng/ml is considered to be very
good and is50 times lower thanwhat has previously been shown
for the standard meningococcal ELISA (8). We did observe that
antibody concentrations determined by the multiplex assay were
lower than those determined by the ELISA for samples with very
low antibody concentrations (data not shown). This has been seen
by others (8) and is believed to be due to the increased dynamic
range of the multiplex, which is better at differentiating between
samples with low levels of antibodies. All in all, this makes the
multiplex assay preferable and highly suitable for use when ana-
lyzing saliva or other types of samples where comparison of very
low antibody levels is relevant.
The difference in sensitivities between the IgG and the IgA
assays might be explained by the different secondary detection
antibodies used, especially by the fact that in the IgA assay the
detecting antibodies are like a sandwich made up of two different
secondary antibodies. However, the sensitivities of the two assays
are well below the likely practical limit for quantitation of 1 ng/ml,
and each is considerably lower than the standard meningococcal
ELISA.
IgG and IgA antibody levels in serum determined by the mul-
tiplex assay and ELISA showed good correlation. When analyzing
saliva, however, no clear correlationwas observed. This can be due
to the low number of saliva samples analyzed and because of the
difference in the two methods’ abilities to analyze samples with
low antibody levels. As previously discussed, the sensitivity and
reproducibility of the ELISA are poorer than for the multiplex
assay, and half of the saliva samples analyzed had antibody levels
below the limit of detection in the ELISA. This may explain the
observed lack of correlation when analyzing saliva samples. The
development and evaluation of the assay developed here, measur-
ing IgA antibodies and analyzing saliva samples, are valuable ad-
ditions to previous work investigating IgG antibodies in serum
only. The reliability, simplicity, and robustness of our assay are
comparable to other meningococcal multiplex assays (8, 11),
which use PLL as a coupling agent instead of DMTMM. In addi-
tion, the method described here avoids the use of toxic chemicals,
such as cyanuric chloride, which is used in the PLL coupling
method (15).
Ourmultiplex assay takes valuable advantage of themultiplex-
ing possibility of the microsphere based flow cytometric technol-
ogy, but as 100 distinct microspheres are available, there is a great
possibility of expanding the assay. Additionally, with replacement
of the monoclonal anti-human IgA secondary antibody only, the
assay will be suitable for detection of other Ig classes; work on this
is in progress. In conclusion, we have developed a simple, specific,
sensitive, and reliable multiplex microsphere assay for the simul-
taneous detection of specific IgG and IgA antibodies against me-
ningococcal serogroup A, C, W, and Y capsular polysaccharides.
The assay shows good correlation to the standard meningococcal
ELISA in serum and is applicable to use for analyzing saliva sam-
ples. It is a convenient alternative to ELISA when investigating the
immune response against multiple meningococcal serogroups.
The method is highly relevant for investigating the effects of me-
ningococcal vaccines, carriage, and disease, as well as for studying
the potential for salivary antibodies as a surrogate for serum anti-
body levels and for immunosurveillance studies.
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